申请人:Vernalis (R&D) Ltd
公开号:US10383871B2
公开(公告)日:2019-08-20
Compounds of formula (I) are inhibitors of fatty acid amide hydrolase, (FAAH), and which are useful in the treatment of diseases or medical conditions which benefit from inhibition of FAAH activity, such as anxiety, depression pain, inflammation, and eating, sleep, neurodegenerative and movement disorders:
Ar1 is optionally substituted phenyl or optionally substituted monocyclic heteroaryl having 5 or 6 ring atoms; Ar2 is optionally substituted phenyl, optionally substituted monocyclic heteroaryl having 5 or 6 ring atoms or optionally substituted fused bicyclic heteroaryl having 5 or 6 ring atoms in each fused ring; and Ar3 is a divalent radical selected from optionally substituted phenylene and optionally substituted monocyclic heteroarylene radicals having 5 or 6 ring atoms.
式(I)化合物是脂肪酸酰胺水解酶(FAAH)的抑制剂,可用于治疗因抑制 FAAH 活性而获益的疾病或病症,如焦虑、抑郁、疼痛、炎症以及饮食、睡眠、神经退行性疾病和运动障碍:
Ar1 是任选取代的苯基或具有 5 或 6 个环原子的任选取代的单环杂芳基;Ar2 是任选取代的苯基、具有 5 或 6 个环原子的任选取代的单环杂芳基或在每个融合环中具有 5 或 6 个环原子的任选取代的融合双环杂芳基;Ar3 是选自任选取代的亚苯基和具有 5 或 6 个环原子的任选取代的单环杂芳基的二价基。